Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Keep at least three days between doses if you change your injection day
A 2.0 mg dose was approved in 2024 for additional glycaemic control
Pharmacol Res 199:107040 Berra C, Manfrini R, Bifari F, Cipponeri E, Ghelardi R, Centofanti L et al (2024) Improved glycemic and weight control with dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting
in the setting of reduced appetite and altered meal patterns, this can unpredictably amplify or destabilize glycemic control
PIONEER 6 established cardiovascular safety with a favorable nonsignificant point estimate [13]
These preclinical observations in rodents promote continued study with the aim of translation to larger animals and specifically primates, the central focus being the quantification of therapeutic index when administered for sustained periods
